Emerg Infect Dis by Cojean, Sandrine et al.
LETTERS
  4.  Simser JA, Palmer AT, Fingerle V, Wilske 
B, Kurtti TJ, Munderloh UG. Rickettsia 
monacensis sp. nov., a spotted fever group 
Rickettsia, from ticks (Ixodes ricinus) col-
lected in a European city park. Appl En-
viron Microbiol. 2002;68:4559–66. http://
dx.doi.org/10.1128/AEM.68.9.4559-
4566.2002
  5.  Sréter-Lancz Z, Sréter T, Széll Z, Egyed 
L. Molecular evidence of Rickettsia hel-
vetica and R. monacensis infections in 
Ixodes ricinus from Hungary. Ann Trop 
Med Parasitol. 2005;99:325–30. http://
dx.doi.org/10.1179/136485905X28027
  6.  Chmielewski T, Podsiadly E, Karbowiak 
G, Tylewska-Wierzbanowska S. Rickett-
sia spp. in ticks, Poland. Emerg Infect Dis. 
2009;15:486–8. http://dx.doi.org/10.3201/
eid1503.080711
  7.  Jado I, Oteo JA, Aldámiz M, Gil H, Escu-
dero R, Ibarra V, et al. Rickettsia mona-
censis and human disease, Spain. Emerg 
Infect Dis. 2007;13:1405–7.
  8.  Paris DH, Blacksell SD, Stenos J, Graves 
SR, Unsworth NB, Phetsouvanh R, et 
al. Real-time multiplex PCR assay for 
detection and differentiation of rickett-
siae and orientiae. Trans R Soc Trop Med 
Hyg. 2008;102:186–93. http://dx.doi.org/
10.1016/j.trstmh.2007.11.001
  9.  Zhang L, Jin J, Fu X, Raoult D, Fournier 
PE. Genetic differentiation of Chinese iso-
lates of Rickettsia sibirica by partial ompA 
gene sequencing and multispacer typing. 
J Clin Microbiol. 2006;44:2465–7. http://
dx.doi.org/10.1128/JCM.02272-05
10.  Di Todaro N, Piazza C, Otranto D, 
Giangaspero A. Ticks infesting domestic 
animals in Italy: current acarological stud-
ies carried out in Sardinia and Basilicata 
regions. Parassitologia. 1999;41(Suppl 1):
39–40.
Address for correspondence: Giordano 
Madeddu, Dipartimento di Medicina Clinica, 
Sperimentale e Oncologica, Università degli 







To the Editor: During 2000–
2010, serial Leishmania isolates 
obtained from an HIV-infected patient 
who was not responding to treatment 
showed a gradual decrease in in 
vitro miltefosine susceptibility. We 
performed L. donovani miltefosine 
transporter (Ldmt) gene analysis 
to identify an association between 
miltefosine resistance of reference 
L. donovani lines and variability in 
miltefosine response of L. infantum 
isolates. A new single-nucleotide 
polymorphism (SNP), L832F, was 
identifi ed, which might be a marker of 
miltefosine resistance in leishmaniasis.
The patient, a 46-year-old 
woman, had lived in France since 
1994 but regularly returned to Algeria, 
her country of birth. HIV-1 infection 
was diagnosed in 1991. Antiretroviral 
therapy was initiated in 1993, leading 
to undetectable viral load and a 
CD4+ T-cell count of 185 cells/mm3 
(reference >450/mm3). Concurrent 
conditions were thoracic herpes 
zoster in 1996, hairy leukoplakia of 
tongue, oropharyngeal candidiasis, 
and chronic renal failure of unknown 
cause since 2000.
Visceral leishmaniasis was 
diagnosed in 1998 by culture of a 
bone marrow smear, which showed 
intracellular amastigotes. Use of 
meglumine antimonate (Glucantime; 
Sanofi , Paris, France), a drug of choice 
for the treatment of leishmaniasis, 
was contraindicated because of 
pancreatitis in the patient and in 
vitro isolate susceptibility variation; 
therefore, induction therapy consisted 
of liposomal amphotericin B (AmpB 
[AmBisome; Astellas Pharma US, 
Deerfi eld, IL, USA]) at a dose of 3 mg/
kg/d for 5 consecutive days, then 1× 
week for 5 weeks (total dose 30 mg/
kg) during 1998–2000 (Table). The 
same medication was administered for 
relapses at 4 mg/kg/d for 5 days, then 
4 mg/kg 1× week for 5 weeks (total 
dose 40 mg/kg) during 2001–2010. 
Given the adverse effects of AmpB 
and the availability of oral miltefosine 
(Impavido; AEterna Zentaris Inc., 
Quebec City, Quebec, Canada), the 
latter drug was used for maintenance 
treatment during 2001–2007 at 50 mg 
2×/d. Leishmaniasis was monitored 
by leukocytoconcentration and culture 
of blood samples on Novy-Nicolle-
McNeal medium.
When signs of biological and 
clinical relapse appeared, bone 
marrow was aspirated for parasite 
detection. After culture of the aspirate 
and isoenzyme determination, the 
strain was identifi ed as L. infantum, 
zymodeme MON-24. Eleven relapses 
were documented; all were confi rmed 
by positive direct examination of bone 
marrow or blood, but cultures of only 
7 samples yielded positive results 
(Table).
The susceptibility of 4 
cryopreserved isolates (S1, S3, 
S4, and S6; Table) to AmpB and 
to miltefosine was studied in the 
in vitro promastigote and axenic 
amastigote form by determining the 
concentrations inhibiting parasite 
growth by 50% (1,2). The 50% 
inhibitory concentration (IC50) 
was determined in parallel for the 
following reference L. donovani 
lines: a wild-type L. donovani LV9 
(MHOM/ET/67/HU3) line (LV9 
WT), a wild-type L. donovani DD8 
(MHOM/IN/80/DD8) line (DD8 WT), 
a laboratory miltefosine-resistant 
line obtained from LV9 WT (LV9 
miltefosine-R, resistant to 90 μmol/L 
miltefosine), and the laboratory AmB-
resistant line obtained from DD8 WT 
(DD8 AmB-R, resistant to 1.4 μmol/L 
AmB) on promastigote and axenic 
amastigote forms (3,4).
The AmB susceptibility of the 
isolates did not change notably over 
time; IC50 values ranged from 0.09 
704 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 18, No. 4, April 2012
LETTERS
μmol/L to 0.24 μmol/L, regardless 
of parasite form, similar to those of 
wild-type reference strains (Table). In 
contrast, the IC50 values of miltefosine 
increased greatly over time, from 5.00 
μmol/L to 50.10 μmol/L. During the 
6 years of follow-up with miltefosine 
maintenance therapy, the susceptibility 
of the isolate (S6) obtained 6 months 
after miltefosine treatment withdrawal 
in 2008 was 6-fold higher than that of 
the fi rst isolate (S1) obtained in 2000.
The L. donovani miltefosine 
transporter protein (LdMT) promotes 
miltefosine translocation (5), and 
LdMT inactivation in L. donovani 
promastigotes leads to miltefosine 
resistance at the promastigote and 
amastigote stages (6). In 2003 and 
2006 studies, several mutations were 
linked to the inability of parasites to 
take up miltefosine and to miltefosine 
resistance (5,7). In a 2009 study, the 
weak expression of LdMT and its β 
subunit LdROS3 in L. braziliensis 
isolates was linked to diminished 
sensitivity (8). We sequenced the 
entire Ldmt gene (3,294 bp) in the 
reference strains and the clinical 
isolates for SNP analysis (5,7). Only 
1 new SNP, L832F, was found in the 
miltefosine-resistant reference strain 
(LV9 miltefosine-R) and in clinical 
isolate S6. The L832 wild-type allele 
was found in isolate S1 and in the 
miltefosine-sensitive reference lines 
(LV9, DD8, and DD8 AmpB-R), 
whereas both alleles were found in 
isolates S3 and S4, with a decrease in 
the wild-type allele (Table). The last 
isolate, which was obtained 3 years 
after miltefosine withdrawal and could 
not be subcultured, had reverted to the 
wild-type allele (L832).
These results point to a relation 
between the 832F allele and diminished 
susceptibility to miltefosine. Analysis 
of this case of miltefosine resistance in 
a patient co-infected with Leishmania 
sp. and HIV strongly suggests that 
an SNP (L832F) in the Ldmt gene 
could represent a molecular marker of 
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Table. Comparions of IC50 for AmpB and miltefosine against promastigotes and axenic amastigotes and distribution of LdMT SNPs in 
Leishmania infantum isolates and reference strains*
Isolate Year AmpB Miltefosine 
IC50, μmol/L ± SEM 
Ldmt
SNP
AmpB  Miltefosine 
Promastigotes
Axenic
amastigotes  Promastigotes 
Axenic
amastigotes
– 1998 3 mg/kg/d  5 d; then 
1 /wk  5 wk 
– – –  – – – 
S1 2000 3 mg/kg/d  5 d; then 
1 /wk  5 wk 
– 0.09 ± 0.04† 0.10 ± 0.03  7.14 ± 0.56† 5.00± ± 0.7† L832 
– 2001 4 mg/kg/d  5 d; then 
1 /wk  5 wk 
50 mg 2 /d – –  – – – 
S3 2005 4 mg/kg/d  5 d; then 
1 /wk  5 wk‡ 
0.13 ± 0.03 0.20 ± 0.03   25.93 ± 1.46†  21.00 ± 1.50† 832L/F 
S4 0.24 ± 0.01† 0.15 ± 0.02 27.89 ± 1.76† 31.90 ± 1.60† 
– 2007 4 mg/kg/d  5 d; then 
1 /wk  5 wk 
– –  – – – 
S6 2008 4 mg/kg/d  5 d; then 
1 /wk  5 wk 
– 0.16 ± 0.03 0.11 ± 0.03  44.30 ± 3.70† 50.10 ± 1.00† 832F 
S7 2010 4 mg/kg/d  5 d; then 
1 /wk  5 wk 
– – –  – – L832 
Reference strain         
 LV9 WT   0.03 ± 0.02 0.02 ± 0.05  4.46 ± 0.29† 6.20 ± 0.3 L832 
 LV9 Miltefosine-R  0.22 ± 0.04 0.70 ± 0.09  45.84 ± 2.40† 54.20 ± 2.20† 832F 
 DD8 WT   0.06 ± 0.02† 0.05 ± 0.03†  17.40 ± 1.70 12.40 ± 1.50 L832 
 DD8 AmpB-R   1.42 ± 0.06† 1.00 ± 0.07†  15.20 ± 1.00 10.30 ± 1.20 L832 
*IC50, 50% inhibitory concentration; AmpB, amphotericin B; Ldmt, Leishmania donovani miltefosine transporter gene; SNP, single-nucleotide 
polymorphism; –, assay not performed because sample unavailable or not culturable; WT, wild type; R, resistant. 
†Significance was analyzed by using the nonparametric Mann-Whitney U test to compare the IC50 of the isolates with the IC50 of reference strains; p<0.01 
was considered significant. IC50 of AmpB and miltefosine was compared with IC50 of reference strains and S1/S3, S1/S4, and S1/S6. Miltefosine: S1/S3,
S1/S4, S1/S6, S4/S6; p<0.01. AmpB: S1/S4 significant p<0.01; S1/S3, S1/S6 not significant. 
‡For each relapse. 
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To the Editor: Two novel 
polyomaviruses (PyVs), KIPyV and 
WUPyV, were identifi ed in respiratory 
and fecal specimens from children with 
signs and symptoms of respiratory tract 
infection (1,2). A review of literature 
on emerging viruses in transplant 
recipients indicated that up to 80% of 
patients harboring these PyVs are co-
infected with another respiratory virus, 
complicating interpretation of positive 
fi ndings (3). Seroprevalence of KIPyV 
and WUPyV in healthy blood donors 
in Germany have been reported to be 
67% and 89%, respectively (4).
The effect of these viruses in 
immunocompromised patients is 
unknown. Some studies report a 
higher frequency of KIPyV DNA 
detection in hematopoietic stem cell 
transplant (HSCT) recipients (5–7) 
than in immunocompetent patients. In 
fact, HCST recipients might be more 
prone to productive infection with 
KIPyV and WUPyV than to infection 
with PyVs JC and BK (BKPyV) (5).
We report prolonged detection of 
KIPyV DNA in the respiratory tract 
of an immunocompromised child. A 
12-year-old girl with severe combined 
immunodefi ciency was admitted to the 
Freiburg University Medical Center, 
Germany, in November 2009 for 
treatment of progressive respiratory 
problems and cytomegalovirus (CMV) 
disease. Although the molecular basis 
of the immune disorder was unknown, 
HSCT was indicated because of 
uncontrolled CMV infection and 
progressive clinical deterioration.
Allogenic HSCT was performed 
in February 2010. Pretransplant 
treatments included thyothepa (day 
−7; 8 mg/kg), fl udarabine (days −6 to 
−3; 120 mg/m2), treosulfan (days –6 
to – 4; 42 g/m2), and antithymocyte 
globulin (days −4 to −2; 45 mg/kg). 
The patient received bone marrow 
cells (4.2 × 106 CD34-positive cells/
kg) from an 8/10 human leukocyte 
antigen-matched, CMV-positive, 
unrelated donor. Graft-versus-host 
disease prophylaxis consisted of 
cyclosporine A (from day −1) and 
methotrexate (days +1, +3, +6; 10 
mg/m2). Leukocyte, granulocyte, and 
platelet engraftment occurred on days 
+18, +19, and +32, respectively. Full 
donor chimera was detected by day 
+62 (Figure, panel A).
Before hospitalization, the child 
had had several pulmonary infections. 
At admission, chest radiograph 
showed middle lobe atelectasis but no 
visible infi ltrates. On day −83, human 
bocavirus was detected. On day −27, 
the occurrence of bilateral infi ltrates 
was assessed, and pneumonia was 
diagnosed. On day +55, fever and 
hypoxia were monitored; chest 
radiograph revealed regressive 
infi ltrates in the lower lobes but 
central infi ltrates in the upper lobes. 
Rhinovirus RNA was detected at this 
time and persisted in the respiratory 
tract until day +98 (Figure, panel 
A). Retrospectively, KIPyV DNA 
was detected in 6 nasopharyngeal 
aspirate specimens, 4 throat swab 
specimens, and 1 bronchoalveolar 
lavage specimen collected between 
days −103 and +98 (Figure, panel B). 
No KIPyV was detected in EDTA-
treated blood samples at any time. 
Stool samples were not available. 
The highest level of KIPyV DNA 
(109 copies/mL) was detected on day 
+16. Starting from day +43, a steady 
decrease in KIPyV viral load was 
observed. Phenotypical analysis of 
blood leukocytes on day +55 showed 
normal CD56+/16+ natural killer cells 
and good T-cell engraftment but no 
B cells. On day +108, viral clearance 
had occurred. Sequencing of the 
small t antigen amplifi ed from all 
available samples was performed (8) 
and showed 100% nucleotide identity 
(GenBank accession no. JN874415).
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